ResearcherUniversity Hospital UlmActive in the last 2 years
Michael Karl Melzer
Matched on ORCID iD 0000-0002-7902-590X; OpenAlex author ID A5089360885, A5140841533. Sources: OpenAlex.
Their work
- Papers
- 6
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 28
2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: none · 2026: 3 papers
Papers 6
- DKK3 Initially Preserves Acinar Integrity Through MEK-Fos Signaling, but Later Switches to an Oncogenic Role in Pancreatic Cancer. Co-author DOI 10.1002/advs.202417606↗
- ATM Deficiency Induces TGFβ-Mediated Stromal Programming in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-26-0138↗
- An oncogenic KRAS-driven secretome involving TNFα promotes niche preparation prior to pancreatic cancer onset. Co-author DOI 10.1186/s12943-025-02541-1↗
- The application of pancreatic cancer organoids for novel drug discovery. Co-author DOI 10.1080/17460441.2023.2194627↗
- State-matched organoid models to fight pancreatic cancer. Co-author DOI 10.1016/j.trecan.2022.03.003↗
- An Immunological Glance on Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/ijms21093345↗
Closest collaborators
The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Alexander Kleger · 6 shared papers, 2020–2026 · strength 1.24
- Paper The application of pancreatic cancer organoids for novel drug discovery. DOI 10.1080/17460441.2023.2194627↗
- Paper State-matched organoid models to fight pancreatic cancer. DOI 10.1016/j.trecan.2022.03.003↗
- Paper DKK3 Initially Preserves Acinar Integrity Through MEK-Fos Signaling, but Later Switches to an Oncogenic Role in Pancrea… DOI 10.1002/advs.202417606↗
- Élodie Roger · 4 shared papers, 2022–2026 · strength 0.86
- Paper State-matched organoid models to fight pancreatic cancer. DOI 10.1016/j.trecan.2022.03.003↗
- Paper DKK3 Initially Preserves Acinar Integrity Through MEK-Fos Signaling, but Later Switches to an Oncogenic Role in Pancrea… DOI 10.1002/advs.202417606↗
- Paper An oncogenic KRAS-driven secretome involving TNFα promotes niche preparation prior to pancreatic cancer onset. DOI 10.1186/s12943-025-02541-1↗
- Thomas Theodor Werner Seufferlein · 4 shared papers, 2020–2026 · strength 0.71
- Paper DKK3 Initially Preserves Acinar Integrity Through MEK-Fos Signaling, but Later Switches to an Oncogenic Role in Pancrea… DOI 10.1002/advs.202417606↗
- Paper An oncogenic KRAS-driven secretome involving TNFα promotes niche preparation prior to pancreatic cancer onset. DOI 10.1186/s12943-025-02541-1↗
- Paper ATM Deficiency Induces TGFβ-Mediated Stromal Programming in Pancreatic Cancer. DOI 10.1158/0008-5472.can-26-0138↗
- Dharini Srinivasan · 3 shared papers, 2026 · strength 0.60
- Paper DKK3 Initially Preserves Acinar Integrity Through MEK-Fos Signaling, but Later Switches to an Oncogenic Role in Pancrea… DOI 10.1002/advs.202417606↗
- Paper An oncogenic KRAS-driven secretome involving TNFα promotes niche preparation prior to pancreatic cancer onset. DOI 10.1186/s12943-025-02541-1↗
- Paper ATM Deficiency Induces TGFβ-Mediated Stromal Programming in Pancreatic Cancer. DOI 10.1158/0008-5472.can-26-0138↗
- Frank Arnold · 3 shared papers, 2020–2026 · strength 0.52
- Paper DKK3 Initially Preserves Acinar Integrity Through MEK-Fos Signaling, but Later Switches to an Oncogenic Role in Pancrea… DOI 10.1002/advs.202417606↗
- Paper ATM Deficiency Induces TGFβ-Mediated Stromal Programming in Pancreatic Cancer. DOI 10.1158/0008-5472.can-26-0138↗
- Paper An Immunological Glance on Pancreatic Ductal Adenocarcinoma. DOI 10.3390/ijms21093345↗
- Chantal Allgöwer · 2 shared papers, 2026 · strength 0.42
- Paper DKK3 Initially Preserves Acinar Integrity Through MEK-Fos Signaling, but Later Switches to an Oncogenic Role in Pancrea… DOI 10.1002/advs.202417606↗
- Paper An oncogenic KRAS-driven secretome involving TNFα promotes niche preparation prior to pancreatic cancer onset. DOI 10.1186/s12943-025-02541-1↗
- Johann Gout · 2 shared papers, 2026 · strength 0.40
- Matthias J. Löhr · 2 shared papers, 2026 · strength 0.40
- Lukas Perkhofer · 2 shared papers, 2026 · strength 0.40
- Yazid J. Resheq · 1 shared paper, 2023 · strength 0.26
- Peter Möller · 1 shared paper, 2026 · strength 0.22
- Paolo Riccardo Camisa · 1 shared paper, 2026 · strength 0.19
- Benedetta Ferrara · 1 shared paper, 2026 · strength 0.19
- Claus Jørgensen · 1 shared paper, 2026 · strength 0.19
- Anton Lahusen · 1 shared paper, 2026 · strength 0.19
- Lorenzo Piemonti · 1 shared paper, 2026 · strength 0.19
- Stefano Crippa · 1 shared paper, 2026 · strength 0.19
- Christopher J. Halbrook · 1 shared paper, 2026 · strength 0.18
- Austin D. Silva · 1 shared paper, 2026 · strength 0.18
- Mohamed Saiel Saeed Alhamdani · 1 shared paper, 2026 · strength 0.18
- Konrad Steinestel · 1 shared paper, 2026 · strength 0.18
- Rima Singh · 1 shared paper, 2026 · strength 0.18
- Patrick Christian Hermann · 1 shared paper, 2026 · strength 0.18
- Alica K. Michels · 1 shared paper, 2026 · strength 0.18
- Roland Rad · 1 shared paper, 2026 · strength 0.18
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.